Literature DB >> 6700792

Novel cytotoxic and antitumor agents. IV. Withaferin A: relation of its structure to the in vitro cytotoxic effects on P388 cells.

J Fuska, A Fusková, J P Rosazza, A W Nicholas.   

Abstract

In vitro effects of withaferin A and its 9 new derivatives on P388 cells have been studied. The cytotoxicity was calculated from the utilization of precursors in protein and nucleic acid (NA) synthesis and from capacity to suppress cell proliferation. The most potent agents proved to be 4-dehydrowithaferin A and withaferin A diacetate exhibited an equal inhibitory effect on thymidine, uridine, and L-valine incorporation. They stopped cell proliferation and, at the same time, killed the cells. Cytotoxicity was found to be due to a double bond at position C2-3, by dissociating this bond the cytotoxicity markedly decreased in all derivatives. A dissociation of the double bond at C24-25 or a removal of OH group from C27 did not cause any significant changes in the biological effects of the derivatives. An addition of a carbonyl group at C4 increased the effects of the agent. An addition of OH groups to the molecule of withaferin A resulted chiefly in a qualitative change in the action of derivatives manifested by a significant decrease in L-valine inhibition. As withaferin A promptly reacted with L-cysteine, it was presumed that one of the possible target sites in the cell might be the SH groups of enzymes which react with the lactone and epoxide groups of the agent.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6700792

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  14 in total

1.  Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells.

Authors:  Mancang Gu; Yanke Yu; G M Kamal B Gunaherath; A A Leslie Gunatilaka; Dapeng Li; Duxin Sun
Journal:  Invest New Drugs       Date:  2013-07-26       Impact factor: 3.850

Review 2.  Withaferin A and its potential role in glioblastoma (GBM).

Authors:  Jasdeep Dhami; Edwin Chang; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2016-11-11       Impact factor: 4.130

Review 3.  Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone.

Authors:  Avani R Vyas; Shivendra V Singh
Journal:  AAPS J       Date:  2013-09-18       Impact factor: 4.009

4.  Withaferin A targets heat shock protein 90 in pancreatic cancer cells.

Authors:  Yanke Yu; Adel Hamza; Tao Zhang; Mancang Gu; Peng Zou; Bryan Newman; Yanyan Li; A A Leslie Gunatilaka; Chang-Guo Zhan; Duxin Sun
Journal:  Biochem Pharmacol       Date:  2010-02-15       Impact factor: 5.858

5.  Microbiological and chemical dehydrogenation of withaferin A.

Authors:  J Fuska; B Proska; J Williamson; J P Rosazza
Journal:  Folia Microbiol (Praha)       Date:  1987       Impact factor: 2.099

6.  Characterization of celastrol to inhibit hsp90 and cdc37 interaction.

Authors:  Tao Zhang; Yanyan Li; Yanke Yu; Peng Zou; Yiqun Jiang; Duxin Sun
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

7.  Development of withaferin A analogs as probes of angiogenesis.

Authors:  Yasuno Yokota; Paola Bargagna-Mohan; Padma P Ravindranath; Kyung B Kim; Royce Mohan
Journal:  Bioorg Med Chem Lett       Date:  2006-03-02       Impact factor: 2.823

8.  The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin.

Authors:  Paola Bargagna-Mohan; Adel Hamza; Yang-eon Kim; Yik Khuan Abby Ho; Nirit Mor-Vaknin; Nicole Wendschlag; Junjun Liu; Robert M Evans; David M Markovitz; Chang-Guo Zhan; Kyung Bo Kim; Royce Mohan
Journal:  Chem Biol       Date:  2007-06

9.  Withanolides-induced breast cancer cell death is correlated with their ability to inhibit heat protein 90.

Authors:  Hui-Chun Wang; Yi-Ling Tsai; Yang-Chang Wu; Fang-Rong Chang; Mei-Hsin Liu; Wen-Ying Chen; Chin-Chung Wu
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

Review 10.  Nature curing cancer - review on structural modification studies with natural active compounds having anti-tumor efficiency.

Authors:  Gurpreet Kaur; Neelam Verma
Journal:  Biotechnol Rep (Amst)       Date:  2015-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.